{"id":"W4394769738","doi":"10.1016/j.esmoop.2024.102974","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Samsung; Society for Immunotherapy of Cancer; Pfizer Japan; Sun Pharma; European Society for Medical Oncology; Fondazione Beretta; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Novartis; Bayer Yakuhin; Veracyte; Boehringer Ingelheim Japan; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Roche; Intas Pharmaceuticals; Relay Therapeutics; Amgen; Pfizer; Institute for Oil Sands Innovation, University of Alberta; AstraZeneca","keywords":"Reimbursement; Breast cancer; Medicine; Family medicine; China; Alternative medicine; South asia; Clinical Practice; Clinical trial; Cancer; Internal medicine; Health care; Political science; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001727141,0.0001802813,0.0002311108,0.00001401598,0.0001099449,0.00006703432,0.0001877735,0.00007192509,0.00001712906],"category_scores_gemma":[0.0001587209,0.00009910412,0.00008198863,0.00006813398,0.0001043905,0.00001797768,0.0001708176,0.00004159763,0.000001613007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002809101,"about_ca_system_score_gemma":0.000154819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006448117,"about_ca_topic_score_gemma":0.003438098,"domain_scores_codex":[0.9990255,0.00004798064,0.0002787864,0.0003889968,0.00009913882,0.000159663],"domain_scores_gemma":[0.9989488,0.0001713151,0.0001054081,0.0002819224,0.0004453055,0.00004724816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003364389,0.0005154353,0.5621056,0.00003548346,0.003869267,0.00000467686,0.00038469,0.000005789405,0.00001153917,0.0001119926,0.03104279,0.3985483],"study_design_scores_gemma":[0.003245189,0.000855174,0.7478746,0.0000897034,0.000668373,0.000005562382,0.0002145138,0.00000915634,0.0004135344,0.00001333828,0.2464642,0.0001467521],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9262249,0.01296285,0.0002707472,0.05148024,0.001279546,0.0041349,0.002784061,0.00003425274,0.0008285198],"genre_scores_gemma":[0.991769,0.004060559,0.001470416,0.0006316324,0.0002718598,0.001228258,0.0001230375,0.00003337301,0.0004118602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3984016,"threshold_uncertainty_score":0.9747667,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05948405414798169,"score_gpt":0.4030207663022943,"score_spread":0.3435367121543126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}